Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPRIME: Pembrolizumab and Docetaxel for Thyroid and Salivary Gland Tumors
NCT03360890Phase 2Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Mar 2018
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in thyroid cancer, salivary gland cancer (SGC), sponsored by University of Chicago. Started Mar 2018; status: active, not recruiting.
02
Drugs
03
Conditions
thyroid cancersalivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT03360890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03360890.